Advertisement

Topics

Chiesi Group Company Profile

06:18 EDT 25th June 2018 | BioPortfolio

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.

Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.

Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.

Location

Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Parma
43100
Italy

Contact

Phone: 39 0521 2791
Fax: 39 0521 774468
Email: info@chiesigroup.com


News Articles [430 Associated News Articles listed on BioPortfolio]

NICE rejects Chiesi’s Lamzede

It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of th...

Chiesi's enzyme disorder therapy approved in EU

Chiesi's marketing application for Lamzede, or velmanase alfa, as long-term enzyme replacement therapy for the treatment of n -More- 

EU green light for Chiesi’s Lamzede

European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosi...

Chiesi, new partner in d·HEALTH Barcelona program

Chiesi, new partner in d·HEALTH Barcelona program28.05.2018

More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE

Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.   

Chiesi's limbal stem cell deficiency drug gets FDA orphan status

Limbal stem cell deficiency drug candidate GPLSCD01 from Chiesi USA received orphan drug status from the FDA. -More- 

Chiesi Committed To Becoming A Major Player In Rare Diseases.

The Italian group has got the green light in Europe for Lamzede, the first disease-modifying therapy for alpha mannosidosis and...    

Chiesi Committed To Becoming A Major Player In Rare Diseases

The Italian group has got the green light in Europe for Lamzede, the first disease-modifying therapy for alpha mannosidosis and...    

PubMed Articles [1797 Associated PubMed Articles listed on BioPortfolio]

Group Influences on Engaging Self-Control: Children Delay Gratification and Value It More When Their In-Group Delays and Their Out-Group Doesn't.

Self-control emerges in a rich sociocultural context. Do group norms around self-control influence the degree to which children use it? We tested this possibility by assigning 3- to 5-year-old childre...

An Examination of Group Size and Valence in Delay Discounting of Shared Outcomes.

Previous research has examined delay discounting in a group context, where the outcomes are shared with others. These studies indicate shallow delay discounting in a group context compared to an indiv...

Ameliorating effects of tempol on methotrexate-induced liver injury in rats.

Methotrexate (MTX) is used in the treatment of certain types of cancers and chronic inflammatory illnesses, although the clinical use of MTX is limited due to its adverse effects, the most common of w...

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Gro...

Nephroprotective Effect of Zingerone against CCl-Induced Renal Toxicity in Swiss Albino Mice: Molecular Mechanism.

The protective effects of Zingerone against CCl induced nephrotoxicity in Swiss albino mice via modulation of metabolizing enzyme, oxidative stress, inflammatory cytokines, and apoptosis. The biochemi...

Clinical Trials [3704 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

Companies [1617 Associated Companies listed on BioPortfolio]

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Chiesi Group" on BioPortfolio

We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Bioethics
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...


Corporate Database Quicklinks



Searches Linking to this Company Record